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 Communities worldwide, especially in the developing world, are afflicted with 
poor-quality medicines disguised as genuine medicines used for treatment of common 
infections. Poor-quality medicines range from expired genuine tablets to placebos 
containing toxins created by criminals. Numerous patients are left with untreated 
conditions, financial losses, and little confidence in the health system. The developing 
world struggles to identify and quantitate poor-quality antimalarial and antibiotic 
medicines. 
 Portable devices employing robust laboratory techniques have the potential to turn 
the tide in this fight. Vast regions in the developing world lack laboratory analysis 
capabilities and therefore need portable instruments to perform medicinal quality 
evaluations. The portable devices lack the demonstrated capability to analyze all classes 
of poor-quality medicines. Results from tested devices reveal a significant gap in 
demonstrating the critical ability to distinguish poor-quality from genuine medicines.  
This study evaluated the Waters QDa mass spectrometer in identifying and 
quantitating common antimalarial and antibiotic medicines. This instrument correctly 
identified all poor-quality medicines among 7 common pharmaceutical treatments. Using 
a high-throughput easily customizable method, the QDa characterized all poor-quality 
medicines, both falsified and substandard. This capability is unparalleled among portable 
instruments. The QDa possesses the ability to become an instrumental asset in the fight 










1.1 The Problem of Poor-Quality Medicines 
Poor-quality medicines posing as genuine, good-quality medicines deceive 
millions of unsuspecting victims every year leaving their conditions untreated causing 
financial loss, diminution of the public health system, and a multitude of preventable 
deaths. These poor-quality medicines include 3 types: falsified, substandard, and 
degraded [1-3]. Falsified medicines are fake medicines with labels containing false 
claims about the content and origin of the medicine. Substandard medicines are 
manufactured by authentic sources but fail to meet good quality standards.  Degraded 
medicines are manufactured by authorized sources but have been spoiled through poor 
management along the supply chain rendering them outside of the good quality standards. 
Further definitions of these terms will be discussed in the section 1.2 [4-8]. 
 The World Health Organization (WHO) established the Global Surveillance and 
Monitoring System (GSMS) to examine the pervasiveness of the poor-quality medicine 
issue including substandard and falsified drugs. In their first 4 years, antimalarials and 
antibiotics were by far the most reported poor-quality medicines accounting for 36.5% of 
the total reported medicines [9]. Poor-quality medicines infiltrate health systems all 
around the world the majority of which pervade regions hardest hit by infectious diseases, 
especially malaria [6, 9, 10].   
Malaria has plagued mankind for centuries by infecting the red blood cells of the 
patient and is caused by the Plasmodium parasites and transmitted through female 
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Anopheles mosquitos [11]. Despite the advancements of modern medicine, malaria 
continues to claim scores of lives every year. In 2016, malaria cases climbed to an 
estimated 2.16 million worldwide; the largest total since 2012. The WHO estimates that 
445,000 people died from malaria in 2016 [10]. The mortality rate decreased by 47% 
from 2000 to 2013 averting the deaths of an estimated 4.3 million people, but has 
gradually decreased by only 4.4% since 2013 [10, 12]. Other studies report even higher 
rates of morbidity and mortality [13]. With 3.2 billion people worldwide at risk for 
malaria and many cases and deaths left unreported, this disease has the potential to 
ravage populations for years to come [12, 13]. 
 Antibiotics are also in high demand worldwide with the most pressing need in 
developing countries. These medicines treat common bacterial infections that range from 
inconvenient ailments to life-threatening illnesses [14]. Over nearly a century, antibiotics 
have improved the lives of people all over the world becoming a pillar of modern 
medicine [15]. It is estimated that over 1 million children perish each year from untreated 
cases of sepsis and pneumonia. Almost half of these deaths are children under the age of 
5 in sub-Saharan Africa. Pneumonia was the second leading cause of death among 
children under the age of 5 in 2013 claiming nearly 935 million lives (preterm birth 
complications being the leading cause of death) [16]. The world needs good quality anti-
infectives to treat malaria and bacterial infections, but unfortunately poor-quality 
medicines are a prevalent danger in the market.  
Most of the literature quotes the WHO International Medicinal Products Anti-
Counterfeiting Task-force (IMPACT) 2006 report finding that 10% of medicines 
worldwide are falsified [3, 11, 17-24].  The report goes on to state that in the developing 
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world defined as regions in Africa, Asia, and Latin America the falsified medicine 
estimates are safely between 10-30% [3, 17, 25].When including all poor-quality 
medicines both falsified and substandards in the developing world the literature ranges 
from 10-50% of medicines [1, 11, 17, 19, 24-27]. Koczwara and Dressman (2017) 
assessed 54 studies covering the globe published between 2007 and 2016 verifying the 
often-cited claim that 10% of all medicines are falsified. The results vary widely 
depending on the region and method employed. They conclude that the available data do 
not support any definitive claims about the pervasiveness of falsified drugs or poor-
quality medicines overall [26]. The literature contains other systematic reviews analyzing 
a multitude of studies investigating this issue revealing no definitive conclusions on the 
precise extent of poor-quality medicines. These studies varied greatly in sampling 
methods, techniques used for analysis, definitions (many had none), and packaging 
assessments among other parameters making them difficult to compare [11, 18-22, 24, 
26, 27].  In many studies, it is uncertain to know if a random and representative collection 
of samples has been achieved [9] and difficult to secure legitimate genuine samples to 
verify results [28]. Comparing these studies illustrates the need for robust, systematic 
guidelines for future studies to produce quality data from strong methodology for any 
defendable conclusions to be produced [5]. Overall, the specific extent of poor-quality 
medicines is unknown.  
Poor-quality medicines inflict grave consequences on the public health system, 
even opening an opportunity for drug resistance to spread. Resistance is a complex, 
multifaceted issue including many proposed mechanisms [29, 30] and theories of 
propagation [11, 31]. Although poor-quality medicines have not been proven to cause 
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resistance, modeling analyses indicate that inadequate dosing of patients opens a path for 
resistance to spread [11, 18, 30, 32, 33]. Substandard and some falsified medicines are 
contributing factors to inadequate dosing. The feasible pathway for spreading resistance 
comes about when a poor-quality medicine containing a sub-therapeutic amount of the 
active pharmaceutical ingredient (API) is used to treat a microorganism, it will not be 
eradicated, but instead adapt allowing it to survive despite the presence of drugs and 
transmit the resistance through other hosts [11, 31, 32].  Drug-resistant mutations 
contribute to treatment failure in which the medicine is unable to eliminate the 
microorganism or resolve the symptoms [11, 31]. In 2016, the WHO reported that 
490,000 individuals developed tuberculosis (TB) that was multi-drug resistant noting that 
drug resistance is major issue with malaria as well [34]. Antimalarial resistance by 
parasites could render current treatments futile and fuel a rise in the mortality rate 
worldwide [12]. 
Falsified medicines can contain toxic levels of impurities and/or incorrect APIs 
causing harmful effects on patients even causing death. Other falsified medicines contain 
correct levels of APIs treating the condition yet robbing the genuine medicine 
manufacturer of profit and possibly containing impurities [26]. Samples of poor-quality 
medicines were found to contain substandard levels of APIs prolonging the illness, while 
others contained toxic levels of APIs causing harm to the patient [20]. In addition to the 
harmful physical effects of poor-quality medicines, the economic impact extends 
throughout the healthcare system. Patients lose hard-earned money on medicines that fail 
to deliver. Legitimate medicine manufacturers suffer both financial and reputational 
losses due to criminal production of poor-quality medicines [14, 26]. A cost analysis 
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study extrapolated a scenario projecting a 10.5% poor-quality medicine rate applied to a 
low or middle income market size, then a loss of around US$ 30 billion would be 
endured in that market [9]. With other estimates reporting higher rates of poor-quality 
medicines, the financial loss felt around the world is crippling. The major issues caused 
by poor-quality medicines including drug resistance, adverse even deadly health effects, 
ineffective treatment, financial loss among others have created a loss of confidence in the 
health system especially in the developing world [1, 3, 9, 18, 26, 31]. 
Globalization advances healthcare around the world, yet also enables criminals to 
manufacture, distribute, and trade poor-quality medicines. The technology and expertise 
available for all to acquire produces avenues for delinquents to infiltrate the public health 
system [2, 3, 9, 23, 26, 35]. Organized crime has laid hold of this opportunity that has 
become a lucrative business with high profit margins [9, 20, 22]. The pharmaceutical 
industry is riddled with entry points for criminals to inject their supply of falsified 
medicines from manufacturing through wholesalers and pharmacies creating an extensive 
and complex problem [9, 12, 22]. One of the most discouraging contributing factors is the 
insufficient legislation and enforcement from governments, especially in the developing 
world. Current laws are woefully incapable of addressing the problem, especially as the 
medicines permeate international trade, and enforcement is crippled by corruption and 
lack of resources [9, 14, 18, 22, 23, 26]. In the developing world, medicinal quality 
assurance is lacking. Current systems are incapacitated by the lack of resources, 
screening technologies, and expertise throughout the supply chain to assess the quality of 
medicines [9, 10, 22, 36]. The immense issues involving poor-quality medicines have far-
reaching, devastating effects mostly inflicting the developing world. 
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1.2 Definitions 
Genuine or good quality medicines are generally defined as products created by 
legitimate, authorized manufacturers following Good Manufacturing Practices (GMP) 
that pass the quality assurance specifications as laid out by the Medicine Regulatory 
Agency (MRA) and continue to follow those standards throughout the entire process 
including the full-term treatment of the patient. Legitimate medicines must be produced 
by traceable, sanctioned manufacturers and maintain quality in order to perform their 
intended function with no unforeseen side-effects [9, 24, 26].  The specifics of definitions 
are of major importance in identifying and addressing poor-quality medicines. 
Universal definitions characterizing specific classes of poor-quality medicines are 
critical but have long been disagreed upon. Since no global set of definitions govern the 
used of these terms confusion and misinterpretation have ensued. Common definitions 
would harmonize future studies revealing the true extent of poor-quality medicines [11, 
22, 26]. The WHO established definitions used by most for classification starting in 1992 
[7] undergoing various revisions to deal with complications and nuances [4, 37]. 
Generally, the latest WHO definitions have been used to scope the types of poor-quality 
medicines [1-3, 5, 24, 26, 35]. Most recently, the WHO clarified the recent set of 
definitions [38] in 2017 adapting the working definitions which serve as the basis used in 
this thesis [8].  
Substandard medicines are also known as “out of specification” defined as 
“authorized medical products that fail to meet either their quality standards or their 
specifications or both.” [8]. These include medicines produced by an authorized 
manufacturer that fail to pass the quality requirements as dictated by the MRA [2, 4, 6]. 
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A key factor involving substandard is that the authorized manufacturer had no nefarious 
motives but rather failed to follow GMP [3].  
Degraded medicines are also produced by registered manufacturers following 
GMPs passing the MRA criteria but later deteriorate outside of the quality standards. This 
is commonly due to a failure to transport or store the medicine under proper conditions 
along the supply chain allowing for the degradation of the components [4, 24]. Exposure 
to harsh climates or direct sunlight can accelerate the degradation of a medicine. The use 
of ‘degraded’ is not as prevalent in the literature as the other two terms since many 
MRAs lack the ability to distinguish degraded from substandard medicines. The 
distinction between degraded and other poor-quality medicines especially substandard are 
critical to correcting the issue [24, 26]. 
Falsified is the term typically used when discussing public health considerations 
and are defined as “medical products that deliberately/fraudulently misrepresent their 
identity, composition, or source. Any consideration of intellectual property rights does 
not fall within this definition. Such deliberate/fraudulent misrepresentation refers to any 
substitution, adulteration, reproduction of an authorized medical product or the 
manufacture of a medical product that is not an authorized product.” [8]. The key aspect 
of falsified medicines is the intentional falsification of a product with regards to the 
packaging, information, components, manufacturer, or any point along the supply chain. 
Falsified medicines could contain the correct API(s) and even within the MRA standards 
but are misrepresenting a different aspect of the medicine. The WHO recognized the term 
“counterfeit” brought on Intellectual Property (IP) rights concerns from pharmaceutical 
companies clarifying the term “falsified” to focus on public health concerns. This issue 
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has caused debates between the two pressing issues of focusing on the health of patients 
but also providing for the prosecution of criminals [4, 24, 26].  
In general, the poor-quality medicines referred to in the literature fall under either 
substandard, falsified, or degraded with counterfeit used when legal ramifications are 
discussed. Adopting universal definitions is paramount in the fight against poor-quality 
medicines framing studies, influencing legislation, and enabling the scientific community 










2.1 Introduction to Current Portable Techniques for Detecting Poor-Quality 
Medicines 
 
This chapter will serve as an abbreviated overview of the current portable 
techniques highlighting relevant specific devices used for identification and quantitation 
of poor-quality medicines. The term ‘portable’ refers to equipment intended to be fully 
functional when deployed into the field, able to be moved by one or two people, with 
minimal set-up required. This does include techniques requiring initial start-up by an 
experienced technician such as the construction of a reference library [39, 40]. After 
initial set-up, the portable technique will be trainable and straightforward for technician-
level operators. Numerous studies failed to include key details such as the sensitivity and 
specificity of the device along with the APIs assessed and a low sample size limiting their 
usefulness [41-44]. The term ‘sensitivity’ refers to the ratio of medicines determined to 
be poor-quality by the device compared to the total number of poor-quality medicines as 
identified by the reference technique. The term ‘specificity’ refers to the ratio of 
medicines determined to be authentic by the device compared to the total number of 
genuine medicines as identified by the reference technique. The challenge with portable 
instruments is miniaturizing complex techniques into robust, trainable and well-tested 
devices demonstrating the capability to identify and quantitate poor-quality medicines. A 
wide range of techniques are represented by portable devices with various levels of 




 High Performance Liquid Chromatography (HPLC) is often used for laboratory 
confirmation testing of poor-quality medicines as the reference technique [26, 41-46]. 
This technique uses a column containing a stationary phase through which the sample 
mixture and mobile phase are forced through separating out the components of the 
sample mixture by their affinity to the stationary or mobile phases. The identity and 
quantitation of the components can be determined by comparing the retention times and 
peak integrations to authentic products [42, 44]. In the developing world, the MRAs lack 
the time, finances, and availability to perform confirmatory analysis from a formal 
laboratory. Frequently the process from collection of suspect medicines through reception 
of test results gives enough time for the poor-quality medicines to permeate the market 
[42-45]. Although HPLC and LC in general is a highly sensitive technique currently it 
still requires facilities, resources, and highly-technical training preventing it from 
deploying into the field [45]. Recently, a study presented the potential for a miniaturized, 
portable LC device capable of in-field analysis [40]. The C-Vue [47], a portable 
laboratory liquid chromatograph, is an inexpensive table-top unit able to separate and 
detect analytes exhibiting UV absorbance. This device demonstrated a specificity of 60% 
and a sensitivity of 100% for both falsified and substandard medicines when tested using 
5 APIs [40]. The C-Vue is limited to APIs displaying UV absorbance, limiting the 
number of potential analytes. Also, a fair amount of sample preparation and data analysis 
training is needed, but the sensitivities of this device especially for determining 
substandard medicines across 5 APIs is unmatched in the literature creating a case for 
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further testing and in-field analysis. Apart from this study, no other portable liquid 
chromatography devices have been reported.  
 The most widely used in-field device is the Global Pharma Health Fund (GPHF) 
Minilab employed in 97 countries, many in the developing world [48]. Over 800 Minilab 
cases have been sold worldwide. This device implements a 3-part method including a 
physical inspection for dosage and packing, a dissolution test, and thin-layer 
chromatography (TLC). In TLC, a small drop of diluted sample is placed on the silica 
plate used as the stationary phase. The bottom of the silica plate is then dipped into a 
mobile phase. Capillary action soaks up the mobile phase which interacts with the sample 
separating out the constituents. The distance traveled and darkness of each spot determine 
the identity and relative concentration of the sample [42, 44, 46]. The semi-quantitative 
Minilab or “lab-in-a-suitcase” contains benchmark TLC standards made at 50%, 80%, 
and 100% of the API for comparison with a sample [46]. The Minilab succeeded in 
identifying the presence or absence of an API, but the variability between analyst 
interpretation of the results leaves this technique only semi-quantitative [26, 44, 46, 49, 
50]. In a WHO study performed across 6 countries in Sub-Saharan Africa only 32% of 
the poor-quality medicines were identified by the Minilab [51]. In Tanzania, 4 different 
APIs (antimalarials and antibiotics) dispersed among 28 samples at 3 concentrations of 
0%, 40%, and 100% of the API analyzed using the TLC method in the Minilab. In the 
first analysis 25 of the 28 substandard samples with 40% API were inaccurately 
identified as being genuine quality. Upon further training, 8 of the 28 were again 
inaccurately identified as being genuine quality [51]. Also in Tanzania, a proficiency test 
led by the country’s Food and Drugs Authority revealed only 5 out of 9 veteran analysts 
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correctly characterized antimicrobial API levels using this method [52]. On the other 
hand, in Ghana a field survey was conducted containing 14 poor-quality medicines 
amongst 84 antimalarials. The TLC results demonstrated 100% specificity and sensitivity 
compared to the reference technique [53]. One study tested 506 samples including 5 
common antimicrobials for evaluating the Minilab against HPLC. The frequency of poor-
quality medicines as determined by the Minilab compared to HPLC, respectively, was 
0% versus 14.9% for amoxicillin and 0% versus 17.4% for azithromycin [49]. Overall, 77 
samples determined to be good quality by the Minilab were in fact poor-quality 
medicines generating a false-negative detection rate of 15.2% [49]. Many of these 
samples contained between 80-100% API concentrations for which the Minilab is not 
designed to detect [46, 49]. While some studies reveal success, overall the Minilab 
demonstrated unsatisfying results in identifying poor-quality medicines, especially 
substandard medicines with API levels close to genuine, further illustrating the variability 
of this technique [26, 44, 46, 49]. The manuals developed for the Minilab were employed 
in this study for the extraction portion of the sample preparation.  
 
2.3 Spectroscopy 
Spectroscopic techniques are the most widely used among portable devices for 
quality drug control. These techniques irradiate the sample with specific wavelengths of 
light instigating molecular vibrations or electronic excitation causing the sample to emit 
or absorb the electromagnetic radiation. The light emitted or absorbed is collected as 
spectra. The spectra produced, called a ‘fingerprint’, is specific to the chemical 
composition of the sample and is compared to a reference library of spectra for a match 
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[43, 44, 54].  These widely available techniques are easy to use, require little or no 
sample preparation involving no reagents, and are noninvasive and nondestructive to the 
sample. [42, 43, 45, 55-57]. Also, some of these handheld spectrometers allow for in-
package analysis of medicines yielding further information for quality assessment [44, 
54, 57].  
Infrared (IR) spectroscopy is commonly employed in handheld devices utilized in 
pharmaceutical analysis, but very few show potential for quantitative analysis of poor-
quality medicines [40, 43, 44, 55, 56, 58]. In IR spectroscopy, the sample is irradiated 
using IR radiation with the transmitted light measured as a spectrum. Certain chemical 
bonds will absorb radiation at characteristic wavelengths and intensities creating a 
distinctive spectrum used to identify the molecule [55, 56, 58]. The MicroPhazir, studied 
by Guillemain et al. (2017), presented a sensitivity and specificity of 100% in 
discriminating genuine and falsified samples with substandard samples absent from this 
study. A key parameter for this instrument, the correlation distance limit, varied 
depending on the medicine type and established through experimentation with genuine 
medicines [56]. This deepens the complexity of the technique potentially causing issues 
in future in-field use along with the complex mathematical models employed [56]. In the 
same study, the SCiO manufactured by Consumer Physics displayed the same level of 
results for falsified medicines. The smartphone-sized SCiO employed in a separate study 
detected falsified medicines with 100% sensitivity along with quantitation of artesunate 
concentrations within ±14.8% with 95% certainty among 15 samples [56]. Unfortunately, 
quantitation was not achievable for the other single API, amodiaquine, and none of the 
combined APIs tested in the study [55].  
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Raman spectroscopy is another common technique employed within portable 
devices [40, 42-44, 50, 54-57, 59]. In Raman spectroscopy, a sample is irradiated with 
electromagnetic radiation most of which is transmitted through the sample while a small 
portion is scattered in all directions. Rayleigh scattering, the majority of the scattered 
light, is elastic since the scattered light frequency is identical to the incident radiation, 
meaning the electron began and ended in the same vibrational state [54, 59]. Raman 
scattering is inelastic since the scattered light frequencies are lower (Stokes scattering) or 
higher (anti-Stokes scattering) compared to the incident radiation. Raman spectroscopy 
measures the inelastically scattered radiation emitted by the sample producing a 
characteristic spectrum revealing the structure of the molecule [54, 59]. The TruScan 
Raman spectrometer, one of only six field tested devices [39, 44, 53], identified falsified 
medicines with a sensitivity of 100% and a 99% specificity [53]. The study also 
evaluated products comprised of a 50% or 150% API content. The device determined all 
4 samples passed revealing the difficulty in characterizing substandards with this device 
[53]. A study by Hajjou et al. (2013) also illustrates the issues with TruScan deciphering 
differences in API strengths between genuine and substandard medicine yet specificity 
and sensitivity calculations were absent. Another handheld Raman device is the 
NanoRam manufactured by B&W Tek [60]. An investigation testing 289 antimalarial 
samples using the NanoRam displayed a 100% sensitivity and 96% specificity when 
determining falsified medicines. Substandard medicines were neglected but identified as 
a potential issue for this device [60]. Raman spectroscopy is limited to analytes not 
displaying fluorescence which saturates the detector making a fingerprint impossible to 
decipher. Fluorescence plagues Raman spectroscopy by exciting many sample 
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components masking the informative scattering signals [39, 59]. Additionally, questions 
remain over combination medicines with one API producing a strong Raman scattering 
signal possibly overwhelming the Raman scattering created by another API [39]. This 
technique also had issues with generic and placebo medicines not performing as expected 
[54, 57, 59]. 
Spectroscopic techniques have some challenges in assessing poor-quality 
medicines. For any spectroscopic technique, the irradiating energy must be resonant with 
the analytes to a detectable level. Handheld devices typically display higher noise and 
lower signal intensities when compared to laboratory instrumentation making some 
medicinal products more difficult to analyze especially low-dosage products [45, 54, 57, 
61]. A reference library is needed for these techniques containing comparison spectra that 
vary depending on API and excipient content as well as brand requiring consistent 
updating and compilation of genuine samples from pharmaceutical companies which has 
proven to be difficult [44, 60]. Also, the coating of certain medicines will likely cause 
issues in analysis using spectroscopic techniques [54, 59]. Overall, spectroscopic 
techniques have demonstrated success in packaging assessment, physical analysis, and 
formulation screening of medicines with some devices able to decipher between genuine 
and falsified medicines yet in general demonstrate significant difficulty distinguishing 
between genuine and substandard medicines [40, 42-45, 53, 54, 56, 57, 59]. 
 
2.4 Colorimetry  
 One device best demonstrating a colorimetric technique is the Paper Analytical 
Device (PAD) [62, 63]. The PAD developed to aid in-field medicinal screening as a low 
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cost, easy to use technique has presented promise with identifying falsified medicines. 
This single-use paper card contains 12 colorimetric chemical tests each giving 
information about the contents of the medicine with limitations on the types of APIs 
available for testing [62]. Prolonged exposure to hot, humid conditions common 
throughout the developing world will deteriorate the capabilities of the PAD the full 
extent of which is unknown [62]. PADs have been tailored to analyze certain 
pharmaceutical medicines such as the antibiotic PAD (aPAD). An investigation using the 
aPAD for quantitative analysis found that 11 out of 50 (22%) amoxicillin substandard 
samples and 7 out of 28 (25%) ampicillin substandard samples were incorrectly 
determined to be genuine. Multiple samples contained API levels between 85-89% while 
the rest of the samples were thermally stressed in the lab possibly influencing the results 
[63]. Colorimetric techniques demonstrated success in identifying the APIs yet require 
sample preparation and display unsatisfying results when analyzing substandard 
medicines. 
 
2.5 Immunoassay  
 Artemisinin-based combination therapies (ACT) were assessed using 
immunoassay dipsticks specific to each type of ACT. Medicine samples are extracted and 
diluted with a few drops distributed onto the dipstick. Color indicators on the dipstick 
reveal the API contents, similar to a pregnancy test [64]. The dipsticks are one of the few 
field-tested techniques analyzing samples from Colombia, India, Papua New Guinea, and 
Zambia. The results of the ACT study did not publish specificity or sensitivity 
calculations, but they were able to identify the correct APIs in the samples [64]. 
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Immunoassay techniques have the potential for further in-field implementation with the 
benefits of no power requirements, low cost, transportable worldwide, and ease of use. 
One major drawback is the antibodies must react with the specific API being assessed, 
meaning each device will be specific to an API potentially causing confusion with 
operators [64]. This device identified the presence of targeted APIs, yet only displayed 
semi-quantitative capabilities and assessed one medicine type. Further testing is needed 
to determine the stability of the dipsticks in tropical climates over time, the tailoring of 
dipsticks to other APIs, and their ability to perform quantitative analysis [44, 64]. 
 
2.6 Microfluidics 
 The best example of a fieldable technique based on microfluidics is the 
PharmaChk device. This is an in-field, prototype device performing a dissolution test 
along with attaching luminescent reagents specific to the API to measure results using 
luminescence [40, 44, 65]. The developers at Boston University continuously incorporate 
user feedback from operators in Ghana to make the device easier to use. The results are 
promising with 0-4% difference compared to the reference technique of HPLC [65]. In 
the future, the goal of this device is to employ a design capable of analyzing multiple 
APIs without necessitating a reference library but currently this device has only tested 
artemisinin-based drugs [40, 65]. This device requires detailed standards preparation and 
uncommon reagents that degrade only hours after preparation [40, 65]. Further testing 





2.7 Capillary Electrophoresis 
Capillary electrophoresis (CE) is a technique separating charged analytes based 
on their movement through a small channel directed by a high electrical field. The 
benefits include no stationary phase, short experimental run time, high separation 
efficiency, and low maintenance. When miniaturized this has shown potential to address 
the problem of poor-quality medicines yet the sample size, sensitivity, and specificity 
were absent [66]. While the instruments are low cost, robust, and portable, they continue 
to involve more reagents in complicated mixtures requiring precise pH values, 
convoluted set-ups and data analyses increasing the complexity of the technique [66-68]. 
More pharmaceutical testing is needed using additional antimalarial and antibiotic 
medicines, large sample sizes, specificity and sensitivity calculations and while deployed 
in the field. 
 
2.8 Counterfeit Detection Device Version 3 Plus (CD3+) 
 The United States Food and Drug Administration (US FDA) developed a low 
cost, battery powered device to analyze the packaging and contents of suspected poor-
quality medicines called the Counterfeit Detection Device Version 3 (CD3+) and has 
been deployed to Ghana [42, 45, 53, 69, 70]. This device equipped with several light-
emitting diodes (LEDs) each shining a single wavelength to monitor the sample response 
while using cameras to capture the images. These images can be compared with the built-
in library or a genuine sample if attainable [69]. This device demonstrated a 100% 
specificity and 98.4% sensitivity when determining counterfeit artesunate samples in one 
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study [69]. Another investigation involving 84 samples compared the CD3+ against the 
Minilab and TruScan devices with HPLC confirming the results. The CD3+ only had a 
specificity of 64% but a 100% sensitivity when weeding out falsified and substandard 
drugs. The study failed to distinguish the specific sensitivities for falsified and 
substandard medicines [53]. This device showed difficulty in identifying genuine samples 
due to variations in packaging from authentic manufacturers. The CD3+ enables 
straightforward, rapid analysis and is substantially less expensive compared to other 
techniques [53]. Further testing is needed evaluating separate categories within poor-
quality medicines including falsified and substandard medicines.  
 
2.9 Mass Spectrometry and Ion Mobility Spectrometry 
 Throughout the world, the need is great for in situ chemical analysis to not only 
identify but also quantitate APIs to aid the fight against poor-quality medicines. Mass 
spectrometry (MS) is a powerful technique with potential to address this issue especially 
as more miniaturized instruments emerge. This technique contains three steps: ionization 
of the analyte(s), sorting and selecting of ions, and detection of the ion abundances with a 
specific mass to charge ratio. The mass to charge ratio corresponds to the potential 
identity of the ion based on molecular formula. Quantitative analysis correlates the 
observed ion abundance with the concentration of the analyte. This technique involves 
sample preparation typically using common reagents and specific standards to compare 
against sample results [44, 71-73]. While the initial cost and training for MS exceeds 
others [44], the capability to quantitate APIs surpasses that of the spectroscopic 
techniques described above. 
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Ion mobility spectrometry (IMS) proven to be a high-throughput and sensitive 
technique requiring little sample preparation has been implemented into rapid screening 
devices [71-73]. IMS separates ions based upon their ion mobility in the gas phase using 
their drift time across a tube filled with an inert drift gas and guided by an electric field 
for identification. The movement of gas phase ions depends upon the charge, shape, and 
size of the ions [71, 72]. This rapid, highly sensitive technique achieves low detection 
limits and does not require solvents, although a buffer gas is required [72]. The SABRE 
4000, manufactured by CBRN Tech Index,  employed in an investigation of dietary 
supplements to analyze sibutramine in low abundance demonstrated the ability to analyze 
samples with a concentration as low as 2 ng/µL [71]. The IONSCAN-LS portable IMS-
MS operating in positive mode showed potential in a study detecting synthetic erectile 
dysfunction drugs (EDD) along with their analogues. The device detected all of the APIs, 
synthetic and analogues, in all 26 herbal supplements tested proving a 100% sensitivity 
and specificity yet was unable to successfully discriminate the identity of two 
contaminants due to their similar mobilities [72].  
The Mini10 handheld mass spectrometer coupled both Desorption Electrospray 
Ionization (DESI) and Electrospray Ionization (ESI) methods with a rectilinear ion trap 
(RIT). While using ESI, this device detected drugs of abuse to the parts-per-billion range 
in an aqueous mixture, but currently there is no assessment of this device in identifying 
poor-quality medicines [74]. 
The Waters QDa mass spectrometer used in this study was previously coupled to 
Direct Analysis in Real Time (DART) ambient ionization to provide rapid chemical 
fingerprinting of antimalarials coupled to a low cost, portable mass spectrometer.  This 
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set-up accurately characterized specific compounds in 192 falsified antimalarials. When 
spectra were compared to a high-resolution quadrupole time of flight (Q-TOF) it revealed 
the loss of very low abundance species, but the base peaks matched in both spectra 
displaying corresponding fingerprints [75]. Only one type of antimalarials were tested, 
the artemether and lumefantrine based ACT, and the ability to quantitate was not assessed 
but left as a potential for future investigation [44, 75]. This thesis will detail the 
assessment of the QDa to identify and quantitate the stated APIs in antimalarial and 
antibiotic medicines using an electrospray ionization ESI source. 
 
2.10 Conclusions on Current Portable Techniques 
 Despite the range of current portable techniques, a great need remains for highly 
sensitive in-field devices to detect and assess all types of poor-quality medicines. A 
thorough review of the literature revealed over 5,718 reports evaluated for portable, in-
field analysis potential narrowing the scope down to 41 portable devices to be assessed 
[44]. After a detailed evaluation of these devices, the authors found a significant lack in 
sensitivity data vital for protecting patient health and the median sample size for each 
device was a meager 2 (1-20) or the tested APIs were not stated at all. Several devices 
demonstrated strong prospective for qualitative analysis, but few were evaluated for 
discovering substandard medicines with even less demonstrating the capability to 
distinguish them from genuine medicines [44]. The training time, implementation cost, 
maintenance, and cost-effectiveness of investing in each device has not been thoroughly 
analyzed [44]. Highly sensitive techniques are often more expensive and difficult to 
develop into a portable version, while many current portable devices are semi-
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quantitative at best and usually require highly experienced technicians using complicated 
methods for each individual API [42-45]. Therefore, it is a necessity to develop, 
thoroughly test, and implement devices capable of in-field qualitative and quantitative 










3.1 Waters QDa Mass Spectrometer  
 In support of the ongoing instrument evaluation effort [40, 44] this study 
evaluates the Waters QDa mass spectrometer (QDa) for rapid analysis of poor-quality 
medicines [76]. This mass spectrometer is designed to be streamlined and straightforward 
from set-up through data analysis yielding mass spectral data with less complexity than 
typical mass spectrometric methods [76-81]. The term mass detector used to describe this 
instrument emphasizes the simplicity and user-friendliness of this instrument by limiting 
ionization parameters and API specific settings alteration needs along with eliminating 
manual calibrations [79, 81]. The QDa has been utilized in drug discovery [79], 
identification and quantitation of drugs of abuse [80], quality control [77], and 
quantitative analysis [78, 81] often coupled with chromatographic separations [77-81].  
Mass spectrometers have three main units including the ionization source, mass 
analyzer, and detector. For this study, the QDa employed an electrospray ionization (ESI) 
source, a series of ion guides, a single quadrupole mass analyzer, and a photomultiplier 
detector (Figure 1). Section 3.1 will briefly explains these specific units. 
 
3.1.1 Electrospray Ionization (ESI) Source 
 The ESI source disperses a solution into an aerosol spray transferring analytes 
from the liquid to the gas phase using an electric field priming ions for analysis using 
mass spectrometry [82-87]. In the 1960s, Malcom Dole, observed mechanics painting  
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Figure 1: Schematic of the Waters Qda mass spectrometer set-up (not to scale). 
 
cars using electrospray creating tiny charged droplets applying the paint evenly across the 
surface. Inspired by the mechanics, Dole coupled the ESI technique with a mass 
spectrometer [83-85, 88]. This soft ionization technique solved the issue of analyzing 
macromolecules using mass spectrometry in a rapid and efficient manner with minimal 
fragmentation [83-85]. Over time, ESI has been a choice technique in analyzing 
biomolecules [83, 85, 89-91], paired with a variety of separation techniques especially 
LC [85, 92, 93], and used in API analysis [94-97]. This robust ionization source has been 
proven to effectively ionize molecules of various sizes, shapes and charges [83, 84, 90, 
98]. ESI is capable of generating either positive (positive mode) or negative ions 
(negative mode). This study used positive mode for most APIs therefore the following 
mechanism description will assume positive mode analysis. Negative mode analysis 
follows the same mechanism except all charges are the opposite of positive mode. ESI 
has three major stages including the formation of charged droplets, reduction of charged  
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Figure 2: Schematic of electrospray ionization (ESI) with the Taylor cone forming at the 





droplet size, and liberation of gas phase ions from the droplets (Figure 2) [82-87]. 
Through these stages, ESI transfers analytes from solution to gas phase ions. 
The protic or aprotic solution used to introduce the analyte into the ESI source 
contains water, methanol or a combination thereof often with small amounts of a weak 
acid or base in order to ensure complete solubility and ionization of the analyte [83, 84, 
87]. 
 In the initial step, ESI creates charged droplets from the incoming solution 
(Figure 2). First, the solution containing the analyte is pumped through a capillary inside 
the probe into the first compartment held at atmospheric pressure. A high voltage is 
applied to the capillary creating an electric field permeating through the solution [82, 84]. 
The electric field induces charge separation migrating the positive ions toward the tip of 
the capillary [83, 85]. The buildup of positively charged ions destabilizes the meniscus 
causing a particularly shaped cone to form called the Taylor cone (Figure 2) [82, 84, 99, 
100]. Inside the Taylor cone, the positive ions accumulating near the end of the cone 
cause an increase in the Coulombic repulsion of the surface charge. Eventually, this 
repulsion is equal to the surface tension of the solution, a point termed the Rayleigh limit 
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[82, 83, 85, 100, 101]. When the repulsion surpasses the Rayleigh limit, a jet of fine 
droplets is sprayed from the Taylor cone into the open air. Each droplet contains an 
excess of positive ions coming off the tip due to the amassing of positive ions [84, 86].  
 As these charged droplets drift away from the Taylor cone, the positive ions 
accumulate around the surface of the droplet. The solvent within the droplets evaporates 
aided by the heated capillary and the desolvation gas, nitrogen in the case of the QDa [79, 
83, 84]. As the solvent evaporates the droplets decrease in size bringing the positive ions 
closer together thus increasing the repulsion force until it overcomes the surface tension 
expelling a stream of progeny droplets in a process called Coulomb fission [82, 85]. 
Experiments completed by Gomez and Tang (1994) captured images depicting a stream 
of progeny droplets emitted from a parent droplet, creating an almost miniature Taylor 
cone [102]. This process of evaporation and fission of the droplets from parent to 
progeny droplets leads to tiny charged droplets becoming the precursors to the gas phase 
ions (Figure 2).  
 The final stage of ESI entails the liberation of gas phase ions from the tiny 
charged droplets (Figure 2). The mechanism by which this final stage progresses is 
described by two prevailing theories. The first method is the charged residue model 
(CRM) first proposed by Dole analyzing molecules with high molecular weight [83, 84, 
88]. This model predicts that the continuous evaporation of the solvent around the 
charged analyte leads to many droplets with a single analyte ion inside. The analyte is 
liberated into the gas phase by evaporation of the remaining solvent [82-85, 103]. This 
theory is typically used to explain the mechanism by which large macromolecule ions 
reach the gas phase [83, 84, 103]. 
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 The ion evaporation model (IEM) developed by Iribarne and Thomson (1976) 
describes their work with small ionic analytes including sodium and chloride ions [104]. 
Based on their experimental results [104] and theoretical calculations [105] Iribarne and 
Thomson theorize that ions collect around the surface of the droplets and directly emit 
from the surface once the droplets decrease to a radius of less than 10 nm [83, 84]. Their 
results led them to conclude that larger molecules followed the CRM process while the 
smaller ions proceeded by the IEM [84, 104, 105]. In IEM, when the droplets become 
sufficiently small, less than a 10 nm radius, ion evaporation replaces Coulomb fission 
expelling the charged ions accumulated on the outer surface of the droplets [83, 84, 104, 
105]. In this final stage of ESI, ions are liberated from the small droplets by either the 
CRM or IEM ready to proceed on to the mass analyzer. 
 
3.1.2 Ion Guides 
 The successive combination of chambers containing ions guides (Figure 1) uses 
electric field and pressure gradients to focus the stream of positive ions into the mass 
analyzer while filtering out neutral, and negative ions. After ESI sprays all species, 
neutral and ionic, into the air, the positive ions must be selected for analysis. Nitrogen gas 
is channeled along the capillary following the trajectory of solvent drying out the droplets 
as well as driving the neutral species away from the opening to the mass spectrometer, 
the cone (Figure 1) [82-85]. Along with the nitrogen, the capillary is heated to assist in 
the evaporation of the droplets [84]. The positive ions produced through ESI are 
electrostatically attracted to the cone by the voltage applied. This cone, orthogonal to the 
capillary, guards the entrance to the second chamber containing a lower pressure than the 
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ambient pressure in the first chamber funneling the ions into the ion guides (Figure 1) 
[82, 85]. The sequence of chambers throughout the mass spectrometer each have lower 
pressure than the previous chamber, creating a pressure gradient attracting the flow of 
ions through the ion guides and mass analyzer to the detector [79, 83, 85]. The off-axis 
ion guides use electrostatic forces to guide positive ions around successive bends while 
sifting neutral ions out of the stream. The next ion guide contains conjoined, stacked 
rings forming the optimal stream of positive ions primed for the mass analyzer [82-85]. 
The use of ion guides assists in eliminating neutral noise along with improving the limit 
of detection and robustness of the instrument [79, 82, 84]. The nitrogen gas along with 
the heated capillary aid the rapid formation of gas phase ions while the electric field and 
pressure gradients create a highly efficient ion transmission through the ion guides 
focusing the optimal stream of ions prepared for the single quadrupole mass analyzer [82-
85].   
 
3.1.3 Single Quadrupole Mass Analyzer 
 Single quadrupole mass analyzers are utilized across the field of MS including gas 
chromatography MS (GC-MS) [106-108], LC-MS [109-111], and inductively coupled 
plasma source MS (ICP-MS) [112-114]. Multiple quadrupole mass analyzers can be 
arranged in succession gaining further information increasing the analysis capability in a 
method termed tandem MS-MS [115-119]. The single quadrupole mass analyzer mimics 
the properties of a runnable bandpass mass filter allowing only a narrow band of 
molecules of a particular mass to charge ratio (m/z) to pass through traversing ahead 
toward the detector [120, 121]. This single quadrupole is referred to as a mass filter  
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Figure 3: Single Quadrupole Mass Analyzer configuration showing the two pairs of rods 
acting as electrodes. One pair has the +DC voltage and oscillating RF voltage (blue) 
while the other pair has the -DC voltage and oscillating RF voltage (red). From this 





because of this aspect. The mechanical simplicity allows the creation of a compact mass 
analyzer to achieve high ion transmission. In addition, the low cost, light weight, high 
scan speed, robustness, easily tunable scanning modes, and low power requirements 
make this mass analyzer uniquely advantageous for portable devices [81, 120-122]. 
Portable devices employing this mass analyzer achieve sensitive, high throughput 
capability typically exhibiting unit mass resolution [81, 122]. 
 The single quadrupole is made of four identical cylindrical rods acting as 
electrodes arranged in parallel along the central axis, z axis (Figure 3). Another option is 
to integrate hyperbolic rods rather than cylindrical, although the QDa contains cylindrical 
[78, 79, 86]. The rods opposite each other are linked electronically with one pair linked to 
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the positive terminal of the direct current (dc) voltage source and the other pair linked to 
the negative terminal. A variable alternating current (ac) is applied to each set of rods as 
well [86, 87, 121]. These ac currents are 180° out of phase with a frequency in the radio 
frequency (RF) range and alternate between positive and negative voltages with each pair 
of rods opposite in sign but equal in magnitude [120, 121]. The combination of the dc and 
ac voltages applied to the four rods creates a mass filtering operation allowing molecules 
with a specific mass to charge ratio to hold a stable trajectory completing successful 
passage on to the detector. One pair of rods is in the x-z plane with a positive dc voltage 
while the other pair of rods is in the y-z plane charged with a negative dc voltage of the 
same magnitude (Figure 3) [123, 124]. In order for an ion to transmit through the mass 
analyzer and reach the detector it must navigate a stable trajectory in both the x-z and y-z 
planes [86, 87]. 
 The pair of rods in the x-z plane are charged with a positive dc voltage and an 
alternating RF voltage. When only the alternating ac voltage is applied to a beam of 
incoming ions, the alternating sign attracts and repels the ions toward and away from this 
pair of rods (Figure 4) [86, 120, 121, 125]. While the rods are charged with a positive 
potential, the positive traveling ions are pushed away from the rods towards the z or 
center axis. During the other half of the cycle when the rods are charged with a negative 
potential the positive ions are attracted towards the rods away from the center axis [87, 
123]. While the negative voltage is applied and an ion hits a rod, it is neutralized and 
eliminated from the beam of ions. Whether or not a positive ion strikes a rod depends on 
multiple factors including the rate of movement along the z axis, mass to charge ratio of 
the ion, and magnitude and frequency of the ac voltage [120, 121]. When the positive dc  
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Figure 4: Single quadrupole mass analyzer rods in x-z plane depicting a) the positive ion 
trajectory towards the center axis while the electrode potential is positive and b) the 
positive ion trajectory away from the center axis while the electrode potential is negative. 
 
 
voltage is overlaid with the alternative ac voltage across the rods in the x-z plane, heavier 
ions follow a stable trajectory. The heavier mass ions will not oscillate as rapidly as 
lighter ions in the electric field, therefore they tend to feel the average potential across the 
rods. This means the positive dc voltage tends to gain the most influence over heavier 
ions focusing the beam of heavy ions toward the z axis [120, 121]. The negative half of 
the ac cycle has minimal effect on the trajectory of these heavier ions. Conversely, lighter 
ions will experience more movement due to the ac current cycle causing many to strike 
the rods eliminating them from the beam of ions [120, 121]. This phenomenon creates a 
filter based upon the mass to charge ratio of the ions. Ions below a particular mass to 
charge ratio will follow an unstable trajectory, strike the rods, and be removed from the 
beam leaving only heavier ions on a stable trajectory toward the detector. The rods in the 
x-z plane charged with positive dc and variable ac voltages perform a high pass mass 
filter only allowing ions with a sufficiently high mass to charge ratio to transmit through 




Figure 5: The single quadrupole mass analyzer acting as a mass filter. A) The high mass 
pass filter created by the quadrupole in the x-z plane. B) The low mass pass filter created 
by the quadrupole in the y-z plane. C) The combination of the high and low mass pass 
filters generating the bandpass mass filter.  
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In the y-z plane, the dc voltage along the pair of rods is equal in magnitude but 
opposite in sign compared to the rods in the x-z plane. The variable ac voltages applied to 
the two pairs of rods are arranged 180° out of phase. As in the x-z plane, heavier ions 
tend to be influenced by the average potential over time. In the y-z plane the dominant 
influence guiding the heavier ions is the negative dc potential inflicting a defocusing 
effect drawing these ions away from the z axis causing removal from the beam [120, 
121]. The static negative dc potential acts upon lighter ions as well although the positive 
half of the ac cycle creates a corrective action avoiding elimination from the beam. In the 
y-z plane the applied negative dc and variable ac potential along the rods performs as a 
low pass mass filter (Figure 5B) [120, 121].  
 Ions traveling through this mass analyzer along the z axis follow oscillating 
trajectories in both x and y directions. In order for an ion to achieve a stable trajectory 
through the entire mass analyzer it must be sufficiently heavy to pass through the heavy 
pass filter regulating the x-z plane as well as sufficiently light to pass through the low 
pass filter regulating the y-z plane. Ions in the mutually stable band representing a select 
mass to charge ratio will pass through the quadrupole eliminating all other ions (Figure 
5C) [120, 121]. The width of the bandpass region is dictated by the ac to dc potentials 
ratio along the rods akin to the resolution of the instrument. These potentials are kept at a 
constant ratio but the magnitude of both are fluctuated in order to tune the center of the 





3.1.4 Photomultiplier Detector 
 The final stage within the QDa is the photomultiplier detector (Figure 6). The 
detector contains a photomultiplier tube (PMT), a device amplifying the incident beam of 
photons or electrons into a cascading flow of photoelectrons striking the detector causing 
a voltage pulse across a resistor commensurate with the amount of incident particles 
[126-128]. This technology first emerged in 1935 designed to leverage secondary 
electron emission within a vacuum phototube amplifying an inbound beam of particles 
suitable for multiple applications including television and sound movies [129, 130]. The 
photomultiplier detector is nearly identical to a scintillator counter used for measuring 
radiation commonly found in handheld survey meters, medical imaging instrumentation, 
homeland security equipment, as well as mass spectrometry [126, 127, 130-134].  
 The beam of positive ions exiting the single quadrupole mass analyzer enters the 
photomultiplier detector (Figure 6). The positive ions strike an oppositely charged 
electrode ejecting multiple secondary electrons. This electrode, called a dynode, emits 
electrons when struck by incident ions converting the ion beam into a stream of electrons 
[128, 135, 136]. These secondary electrons then collide with a phosphorous screen 
exciting the atoms releasing photons. The photons are directed towards the PMT striking 
the photocathode connected to the negative terminal of a high voltage source [98, 127, 
135, 136]. When struck by the photons, electrons are ejected into the PMT, one electron 
per photon. The PMT (Figure 7) contains a series of dynodes held at increasingly positive 
potentials creating an electric field guiding the electrons through the tube striking each 
dynode [121, 126, 135]. An electron colliding with the first dynode releases multiple 




Figure 6: Schematic of a photomultiplier detector operating in a) positive mode and b) 
negative mode. The stream of ions enters the photomultiplier detector striking the 
conversion dynode releasing secondary electrons which collide with a phosphorescent 
screen. This collision releases photons that strike the photocathode of the photomultiplier 









Figure 7: Schematic of a photomultiplier tube (PMT). The photons seen in Figure 6 
collide with the photocathode releasing an electron into the PMT. These electrons strike 
the first dynode initiating a cascade of electrons streaming from dynode to dynode. The 
series of dynodes contain increasingly positive potentials causing the flow of electrons 





electrons are released when the second dynode is pummeled by the electrons creating a 
cascade of electrons significantly amplifying the original signal from the incident beam 
[127, 128, 135]. A PMT will typically contain ten or more dynodes. This torrent of 
electrons reaches the anode causing a pulse in the voltage held across resistors measured 
as the signal corresponding to the amount of initial ions (Figure 7) [98, 126, 127, 135]. 
This detector operates similarly to an electron multiplier yet avoids the issue of surface 
contamination on the photocathode by striking the surface with photons instead of 
particles [98, 135, 136]. For this study, mainly positive mode was used, but negative 
mode is available using the second dynode within the detector (Figure 6) [128, 135, 136]. 
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The photomultiplier eliminates contamination and is held in a vacuum environment 
extending the lifetime while providing a rapid, highly sensitive, and robust detector 
capable of being miniaturized for implementation inside portable instrumentation [98, 
127, 128, 135].   
 
3.2 Procedure 
 The following protocol outlines the procedure completed for rapid, high-
throughput analysis of 11 APIs that include: amoxicillin (A) & clavulanic acid (CA), 
artemether (AM) & lumefantrine (LM), artesunate (ART), azithromycin (AZITH), 
dihydroartemisinin (DHA) & piperaquine (P), ofloxacin (OFLO), and sulfamethoxazole 
(SM) & trimethoprim (TM). Eight of these APIs are co-formulated combinations inside 
medicines creating 7 different pharmaceutical treatments evaluated in this study. The 
standards of these APIs were purchased from TCI Chemical (A, AM, LM, ART, AZITH, 
DHA, OFLO, SM, and TM), Sigma Aldrich (CA), and Alfa Aesar (P). This study 
evaluated a series of genuine, substandard, and falsified medicines for every API or API 
combination. For each API or API combination, between 1 and 4 field collected good 
quality (FCGQ) medicine(s) were evaluated along with 9 field collected falsified 
medicines tested for AMLM and 1 tested for SMTM. The majority of the medicines 
employed in this study were simulated tablets manufactured in the lab across all three 
classifications: genuine, substandard, and falsified. Genuine medicines created in the lab 
mimicked the API concentrations and excipient ratios exactly. The simulated medicines 
created in the lab included 3 with 80% of the correct API concentration and 3 with 50% 
of the correct API concentration along with a common excipient mixed into the tablet. 
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The 3 common excipients used across all medicine classifications included lactose, 
cellulose, and starch all from Sigma Aldrich. The 6 simulated falsified medicines created 
in house included 3 containing an incorrect API, acetaminophen, one excipient, and 0% 
of the API concentration while the other 3 consisted of pure excipient. Every API or API 
combination was tested across all classifications and origins including genuine (FCGQ 
and simulated), substandard (simulated), and falsified (simulated and field collected when 
available).  
The protocol included sample and standards preparation, QDa set-up, and the data 
analysis methodology (Figure 8). The software MassLynx 4.0 employed in conjunction 
with the QDa facilitated settings configuration, data collection and processing. The 
specific details and settings pertaining to each API or API combination are listed in Table 
1. This protocol contains the extraction steps adopted from the GPHF Minilab [48] and 
can be conducted using the materials and measuring devices contained within the “lab-in-
a-suitcase” [46, 137]. 
 The sample preparation began with weighing and crushing the pill in aluminum 
foil or weigh paper. The extraction solution was made with a portion of the pill and the 
appropriate solution (Table 1). This was followed by the creation of dilution 1 and 2 
solutions in succession according to the specifications in Table 1. The target 
concentration is the concentration a good quality medicine, 100% API concentration, will 
attain following this protocol. The sample aliquots were drawn from the dilution 2 
solutions and injected into the QDa through the six-port injector. The standards used to 
create the calibration curve followed the same protocol as the corresponding samples for 
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Figure 8: Protocol for QDa experiments. Stock standards were used to create calibration 
standards while medicines were crushed, extracted and diluted for testing. The signal 
intensity or abundance was recorded and plotted. The medicine concentration was 




covered the expanse of the concentration range ideally with two calibration standards 
above and below the target concentration along with an optional fifth calibration standard 
at the target concentration.  
 The QDa set-up began with completing the internal calibration. This instrument 
allows for internal or external calibration upon initial startup with internal calibration 
employed in this study. In the MassLynx 4.0 software, specific MS method settings files 
corresponding to each API and API combination loaded established parameters (Table 1) 
guiding the flow of ions from sample injection through detection and accumulation of ion 
counts or abundances.  
 The experimental runs began with the calibration standards introduced in 
succession from lowest to highest concentration injected in triplicate allowing the signal 
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to reliably reach the background between injections. An aliquot of the mobile phase 
injected in between standards cleaned the sample loop eliminating contamination 
between standards. After calibration, questioned samples were inserted in the same 
triplicate manner followed by an aliquot of the mobile phase. The data recorded during 
each experimental run contained the single ion recording (SIR) chromatogram for each 
preselected m/z value (Table 1). The resulting chromatogram displayed the ion counts or 
abundance at the specified m/z value(s) from each injection as a peak (Figure 9).  
 The data analysis conducted using the chromatogram started by smoothing the 
data. The chromatogram depicted a series of peaks each corresponding to an injection of 
calibration standard or sample (Figure 9). The area under each peak corresponded to the 
abundance of the ions at the specified mass to charge ratio within the injection. A 
calibration curve created from the calibration standard abundances used the linear 
regression model producing an equation. The abundances of suspect samples were 
entered into the linear regression equation calculating a concentration value. This output 
concentration value was compared with the target concentration to calculate the 
difference reflected as a percentage. The sample must yield a concentration within 10% 
of the target concentration for a medicine tablet to be declared good quality. If a sample 
is outside the ±10% window, the medicine is determined to be poor-quality. This ±10% 
passing benchmark was adopted from the United States Pharmacopeia (USP) definitions 
using HPLC in quantifying multiple APIs employed in this study [138, 139]. A medicine 
was considered a pass if 2/3 injections of the API(s) passed. In a binary co-formulation, 
2/3 of both API injections must pass for the medicine to be determined genuine. If 2/3 
injections of the API(s) fail, then the medicine was determined to be poor-quality. The  
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Figure 9: Single ion recording (SIR) mode chromatogram for an ofloxacin experimental 
run. The run began with the calibration standards followed by the samples all injected in 




testing and analysis of all medicines proceeded through this protocol with results 




RESULTS AND DISCUSSION 
 
4.1 Total Ion Current (TIC) mode versus Single Ion Recording (SIR) mode 
 At the onset of the method development stage, each experiment employed the 
total ion current (TIC) mode for recording the abundances. In TIC mode, the voltages 
within single quadrupole mass analyzer rapidly fluctuate sweeping the bandpass filter 
through a large range of mass to charge ratios (Figure 5). This sweeping action is 
described as scanning through a predetermined range of mass to change ratios collecting 
abundances of ions across the range. The quadrupole will only allow ions of a single 
mass to charge ratio to traverse through during a fraction of the total time. While 
employing TIC in experiments, the linear regression calculations revealed adequate but 
the coefficients of determination (R2) were not optimal (Figure 10). TIC offers the ability 
to sweep across a large range in order to determine the dominant analyte species and 
identify potential contaminants in the sample. Single ion recording (SIR) mode centers 
the bandpass filter on a single mass to charge ratio for the entirety of the experimental 
run. This keeps the mass analyzer electronics set to allow ions of the specified mass to 
charge ratio to traverse on to the detector. The linear regression calculations revealed 
excellent linearity values increasing the robustness of the data with greater precision and 
accuracy (Figure 10). The average relative standard deviation (RSD) across the 
calibration curve for the TIC run was 13.6% while the SIR mode run displayed an RSD 
of 2.4%. This improvement became crucial when evaluating medicine samples because  
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Figure 10: Experimental runs employing identical parameters using a) total ion current 
(TIC) mode and b) single ion recording (SIR) mode. The linear regression calculations 
determined the linearity of each line displayed as the R2 value with the SIR mode 




of the tight ±10% window to be declared a pass. SIR mode became the established setting 
across all APIs for experimental runs. TIC mode could be employed in order to determine 
the dominant species as well as find impurities. 
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4.2 Sample Results 
 The goal of this study was to evaluate the ability of the QDa to perform rapid, 
high-throughput analysis of poor-quality medicines. The specificity and sensitivity results 
of this study are summarized in Table 2. The specific results for every medicine tested are 
listed in Appendix A.1. A total of 123 samples were analyzed across three domains of 
medicine: genuine, falsified and substandard. The sensitivity and specificity calculations 
were completed using the true-positive, true-negative, false-positive, and false-negative 
values [49, 140]. A true-positive is a poor-quality medicine determined to be poor-quality 
by the instrument. A true-negative is a genuine medicine determined to be genuine by the 
instrument. A false-positive is a genuine medicine determined to be poor-quality by the 
instrument. Finally, a false-negative is a poor-quality medicine determined to be genuine 
by the instrument. Ideally, an instrument would have only true-positives and true-
negatives without any false-positives or false-negatives. In this study, the QDa 
determined 95 true-positives, 21 true-negatives, 7 false-positives, and 0 false-negatives. 
The binomial specificity and sensitivity calculations incorporated these values.  
 
QDa Sensitivity and Specificity Calculations 
Genuine (n=28) 
Specificity (95% CI) 
Falsified (n=53) 
Sensitivity (95% CI) 
Substandard (n=42) 
Sensitivity (95% CI) 
All PQMs (n=95) 
Sensitivity (95% CI) 
75 (55.1-89.3) 100 (93.3-100) 100 (91.6-100) 100 (96.2-100) 
 
Table 2: The QDa sensitivity and specificity calculations from this study using 123 
samples across three classes of medicines: genuine, falsified, and substandard. The 
binomial calculations employed a 95% confidence interval (CI) shown in the parentheses. 
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The specificity when analyzing genuine medicines was 75% (55.1-89.3) with a 
95% confidence interval (CI). This includes FCGQ and tablets created in the lab. The 
QDa displayed a competitive specificity compared to other techniques [42, 44, 53, 54] 
while holding a strict ±10% passing standard. If desired, further testing could establish a 
unique QDa passing standard potentially allowing greater specificity without 
compromising the sensitivities. The QDa proved considerably effective in filtering out all 
poor-quality medicines. The sensitivities of both falsified and substandard medicines 
were 100% (93.3-100) and 100% (91.6-100), respectively, combining to demonstrate a 
sensitivity of 100% (96.2-100) when evaluating poor-quality medicines. Studies rarely 
analyzed separate categories of poor-quality medicines especially in double digit 
quantities revealing moderate falsified sensitivities yet limited success with substandard 
sensitivities. Common portable devices have identified falsified medicines evaluating a 
few APIs [44, 53] yet the lack of breadth and depth in testing antimalarial and antibiotic 
medicines remains. Substandard medicines continue to plague patients with portable 
devices unable to differentiate them. The ability of the QDa to characterize substandard 
medicines from genuine and falsified medicines provides a potential solution for this 
problem. In this study, the QDa determined 0 false-negatives allowing none of the poor-
quality medicines to infiltrate the pool of genuine medicines. The successful results from 
this device demonstrate the capability of the QDa to potentially become a pivotal 
instrument in the fight against poor-quality medicines.  
Representative calibration curves of ofloxacin, azithromycin and on co-
formulated medicine, sulfamethoxazole and trimethoprim, are displayed in Figure 11. 
The linear regression calculations determined the coefficients of determination (R2).  
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Figure 11: Calibration curves for OFLO, AZITH and one co-formulated combination of 
SM and TM with the concentration along the x-axis and the abundances displayed as ion 





These values being close to 1 demonstrated the calibration standards were within a 
suitable linear range for each API. The equations produced from the linear regression 
calculations were used to determine the concentration of each sample injection. 
Representative calibration curves for the rest of the APIs are in Appendix A.2.  
 
4.3 Advantages 
 The QDa presented multiple advantages compared to the current portable devices. 
First, this device demonstrated a robust capability to separate poor-quality from genuine 
and falsified from substandard medicines, as revealed by the unprecedented sensitivities. 
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By employing specific definitions and evaluating both falsified and substandard 
medicines, the QDa displayed greater in-depth analysis of poor-quality medicines than 
previous devices. The satisfactory specificity of this device displayed the ability of the 
QDa to identify genuine medicines comparable to other portable devices while holding to 
strict passing standard and those studies mostly tested a smaller sample size. This study 
employed more APIs with more samples than typical device evaluations and conducted 
more in-depth poor-quality medicine distinctions [44]. The numerous APIs employed in 
this study encompassed many common antimalarials and antibiotics, some not yet tested 
with portable devices with the QDa showing strong potential to analyze even more. The 
rapid, high-throughput capability of the QDa makes it an asset in the continued fight 
against poor-quality medicines.  
This device employs mass spectrometry a widely recognized, robust technique 
capable of identifying and quantitating analyte APIs, recognizing contaminant APIs, and 
producing a specific chemical fingerprint [75]. The current set-up of the QDa provides an 
efficient, sensitive, and durable instrument from ionization source through the detector 
[75, 84, 120, 136]. This instrument is designed to swiftly analyze various types of 
molecules within the 30-1250 mass to charge range with limited fragmentation [76, 84]. 
By utilizing mass spectrometry, the QDa provides thorough compositional analysis to 
decipher between genuine, falsified and substandard medicines. This instrument is light 
weight (65 lbs) and low cost (US$ 75,000) in relation to laboratory mass spectrometers 
with the start-up cost comparable to some portable spectrometers [44]. The start-up cost 
although steep for the developing world will acquire an effective device for medicine 
quality assurance. 
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Training this technique would be comparable to other techniques. The sample 
preparation is one additional step to the Minilab protocol [137] utilizing similar reagents 
and supplies [48, 49, 137]. Methods for the API and API combinations used in this study 
would serve as a spring board for future implementation with the ability to add other 
APIs following similar preparation and parameter settings. The user-friendly data 
analysis software allows for in-depth compositional analysis without requiring in-depth 
knowledge of data manipulation. Veteran technicians familiar with the protocol and data 
analysis could incorporate new medicines expanding the analysis portfolio. Implementing 
the QDa in the field would enable technicians to evaluate the quality of medicines 
throughout the supply chain discovering crucial intelligence in the fight against poor-
quality medicines.  
 
4.4 Disadvantages 
The results reveal the QDa is capable of aiding the fight against poor-quality 
medicines although issues stem from the resources needed and requirements to run the 
instrument. The largest obstacle to implementing the QDa is the start-up cost. The 
instrument is US$ 75,000 also requiring a solvent pump, liquid nitrogen dewars, as well 
as laboratory grade reagents, glassware, and scales. The steep initial cost pays off as the 
QDa provides more in-depth analysis compared to other portable techniques some of 
which also carry a large initial cost. The cost of reagents, glassware and scales from 
regular use of the instrument is manageable. Routine cleaning and maintenance of the 
instrument requires additional training, parts, cleaning solvents, and time. If additional 
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issues requiring maintenance arise then professional help would need to be made 
available either virtually or in person.  
The training and expertise needed for operating the instrument is higher compared 
to other techniques. Mass spectrometry is highly sensitive but requires delicate and 
precise preparation and execution to avoid contamination. Various techniques require 
little to no sample preparation whereas the QDa requires detailed and specific sample 
preparation increasing the time needed for sample throughput. Troubleshooting issues 
with the QDa could cause difficulty due to the increased level of mechanical and 
experimental complexity of the instrument.  
An additional significant obstacle is the nitrogen supply required as the 
desolvation gas for the instrument. The cost and consistent supply of nitrogen will be 
prohibitive in many places around the world. Also, the QDa requires a stable power 
supply in order to operate. An unstable power supply would cause trouble in operating 
the QDa. The necessary supply of nitrogen and power will limit the spread of the QDa 
inhibiting use in more rural and remote locations where other portable techniques can 
reach. The opportunity remains for the QDa to reach further into the developing world 
than current highly sensitive techniques enabling comprehensive, expedient medicine 
quality assurance testing where previously absent.  
In this study, the QDa demonstrated the ability to conduct high-throughput 
analysis of poor-quality medicines. The practical aspects of the QDa including the initial 
cost, continuous supply of reagents, and necessary nitrogen and power requirements 




 Poor-quality medicines inflict a devastating toll on healthcare systems especially 
in the developing world. These medicines wreak havoc by robbing patients of treatment 
and causing further health issues creating a loss of confidence in the health system. The 
use of these medicines opens an opportunity for drug resistance to flourish. Studies 
seeking key information on the pervasiveness of the issue yield only glimpses into the 
multifaceted, devastating situation worldwide. The full extent, consequences, and 
complexity of the problem continues to be unknown.  
 Portable devices designed to address this issue bring proven analytical techniques 
into the field. Highly sensitive techniques rendering detailed compositional information 
have yet to be converted into a portable device capable of rapid analysis. Portable devices 
undergoing evaluation have overall demonstrated moderate success in identifying 
falsified and genuine medicines yet lack the quantitative ability to characterize 
substandard medicines. The QDa displayed respectable success in the specificity of 
genuine medicines while employing a stringent ±10% pass standard. The unrivaled 
success of the QDa in demonstrating excellent sensitivities of falsified and substandard 
medicines forges the case for further testing and implementation in the fight against poor 
quality medicines. The rapid, high-throughput analysis of medicinal quality illustrated in 
this study employed a trainable technique using specifically tailored methods for 7 APIs 
or API combinations. The QDa performed in-depth evaluation of these common 
antimalarials and antibiotics yielding promising results in an efficient manner. The 
practical limitations of the QDa prohibit this device from reaching many remote areas 
that other portable techniques could, yet the information gained in utilizing this device 
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merits further testing and implementation to locations able to sustain this technique. The 
QDa therefore garners the classification of semi-portable. Upon further successful testing 
of the QDa in determining genuine, falsified, and substandard medicines, this device 
could arm MRAs, authorized manufactures, and others with a formidable tool in the fight 








QDa Sample Data from all Active Pharmaceutical Ingredients (APIs) 
 
 
Table 3: The tables below contain the data from medicines containing a) ACA, b) 
AMLM, c) ART, d) AZITH, e) DHAP, f) OFLO, and g) SMTM. The “sim” stands for 
simulated medicines created in the laboratory; “LAC” means the excipient is lactose; 
“CEL” means the excipient is cellulose; “STR” means the excipient is starch; “FC” 
means a field collected sample; “ND” means not detected indicating no abundances 
counted above the background due to the injection. The results are a ratio of the 
calculated concentration compared to the expected concentration of an injection from the 
target concentration (100% API(s)). All results within ±10% of the target concentration 
pass (green), all others fail (red). Medicines are considered good quality if the API(s) 















Sample ID Sample Type Injection 1 Injection 2 Injection 3 Injection 1 Injection 2 Injection 3
RC-ACA Sim 100% APIs 105.2 105.8 100.2 105.7 102.4 99.2
SS80-ACA-LAC Sim substandard 80% APIs 81.8 81.3 72.8 85.1 89.7 72.3
SS80-ACA-CEL Sim substandard 80% APIs 83.0 84.9 75.9 84.8 81.9 76.3
SS80-ACA-STR Sim substandard 80% APIs 90.4 90.7 90.9 88.9 86.8 82.9
SS50-ACA-LAC Sim substandard 50% APIs 50.3 50.1 46.9 60.8 63.0 55.9
SS50-ACA-CEL Sim substandard 50% APIs 55.1 55.1 47.1 58.4 57.2 56.2
SS50-ACA-STR Sim substandard 50% APIs 57.2 57.6 53.1 65.3 60.7 54.4
EX-LAC Sim falsified 100% excipient ND ND ND ND ND ND
EX-CEL Sim falsified 100% excipient ND ND ND ND ND ND
EX-STR Sim falsified 100% excipient ND ND ND ND ND ND
SM-ACET-LAC Sim falsified Acetaminophen with 0% APIs ND ND ND ND ND ND
SM-ACET-CEL Sim falsified Acetaminophen with 0% APIs ND ND ND ND ND ND
SM-ACET-STR Sim falsified Acetaminophen with 0% APIs ND ND ND ND ND ND
Augmentin (G563) FCGQ 102.0 102.2 94.4 90.0 89.4 82.4
Cavumox (G528) FCGQ 108.9 109.4 96.8 96.0 99.8 84.5





Sample ID Type Of Sample Injection 1 Injection 2 Injection 3 Injection 1 Injection 2 Injection 3
RC-AMLM Sim 100% APIs 104.0 102.9 107.9 90.2 87.5 90.1
SS80-AMLM-LAC Sim substandard 80% APIs 69.3 69.1 71.4 78.7 74.7 73.9
SS80-AMLM-CEL Sim substandard 80% APIs 67.7 67.9 69.7 76.5 72.0 72.0
SS80-AMLM-STR Sim substandard 80% APIs 77.1 72.5 72.6 75.4 68.8 69.3
SS50-AMLM-LAC Sim substandard 50% APIs 38.1 35.2 40.2 47.0 44.2 44.0
SS50-AMLM-CEL Sim substandard 50% APIs 46.8 42.5 44.2 44.9 41.9 42.1
SS50-AMLM-STR Sim substandard 50% APIs 58.1 60.5 59.8 46.3 44.1 43.6
EX-LAC Sim falsified 100% excipient ND ND ND ND ND ND
EX-CEL Sim falsified 100% excipient ND ND ND ND ND ND
EX-STR Sim falsified 100% excipient ND ND ND ND ND ND
SM-ACET-LAC Sim falsified Acetaminophen with 0% APIs ND ND ND ND ND ND
SM-ACET-CEL Sim falsified Acetaminophen with 0% APIs ND ND ND ND ND ND
SM-ACET-STR Sim falsified Acetaminophen with 0% APIs ND ND ND ND ND ND
Coartem (K19) FCGQ 102.8 100.7 105.9 95.6 88.7 89.0
LC15 FC Falsified ND ND ND ND ND ND
LC5 FC Falsified ND ND ND ND ND ND
LC9 FC Falsified ND ND ND ND ND ND
N1 FC Falsified ND ND ND ND ND ND
N15 FC Falsified ND ND ND ND ND ND
N19 FC Falsified ND ND ND ND ND ND
N3 FC Falsified ND ND ND ND ND ND
N34 FC Falsified ND ND ND ND ND ND
N36 FC Falsified ND ND ND ND ND ND
N5 FC Falsified ND ND ND ND ND ND
Table 3B Artemether Conentration (%) Lumefantrine Concentration (%) 
Sample ID Type Of Sample Injection 1 Injection 2 Injection 3
SM-ART Sim 100% APIs 106.0 110.0 101.9
SS80-ART-LAC Sim substandard 80% APIs 70.9 68.2 74.8
SS80-ART-CEL Sim substandard 80% APIs 78.9 80.7 77.3
SS80-ART-STR Sim substandard 80% APIs 77.9 79.3 80.8
SS50-ART-LAC Sim substandard 50% APIs 47.4 46.8 47.3
SS50-ART-CEL Sim substandard 50% APIs 49.9 52.1 51.9
SS50-ART-STR Sim substandard 50% APIs 69.4 69.2 69.4
EX-LAC Sim falsified 100% excipient ND ND ND
EX-CEL Sim falsified 100% excipient ND ND ND
EX-STR Sim falsified 100% excipient ND ND ND
SM-ACET-LAC








Sim falsified Acetaminophen 
with 0% APIs
ND ND ND
Artesun G548-2 FCGQ 110.1 110.6 109.3









Sample ID Type Of Sample Injection 1 Injection 2 Injection 3
SM-AZITH-LAC Sim 100% APIs 97.8 101.2 103.4
SM-AZITH-CEL Sim 100% APIs 90.0 92.8 95.8
SM-AZITH-STR Sim 100% APIs 92.1 95.0 93.7
SS80-AZITH-LAC Sim substandard 80% APIs 74.1 83.7 85.7
SS80-AZITH-CEL Sim substandard 80% APIs 81.4 87.7 85.3
SS80-AZITH-STR Sim substandard 80% APIs 84.5 80.9 79.1
SS50-AZITH-LAC Sim substandard 50% APIs 51.8 54.9 55.0
SS50-AZITH-CEL Sim substandard 50% APIs 47.2 52.1 51.0
SS50-AZITH-STR Sim substandard 50% APIs 49.4 53.3 51.9
EX-LAC Sim falsified 100% excipient ND ND ND
EX-CEL Sim falsified 100% excipient ND ND ND
EX-STR Sim falsified 100% excipient ND ND ND
SM-ACET-LAC








Sim falsified Acetaminophen 
with 0% APIs
ND ND ND
Oralzicin (LA 17/06) FCGQ 96.6 96.9 98.1
Azithromax (LA 16/15) FCGQ 90.9 91.9 89.8
Table 3D Azithromycin % Concentration
Sample ID Type Of Sample Injection 1 Injection 2 Injection 3 Injection 1 Injection 2 Injection 3
RC-DHAP Sim 100% APIs 103.7 99.4 103.9 106.8 110.5 106.3
SS80-DHAP-LAC Sim substandard 80% APIs 52.2 52.9 49.2 88.8 89.7 89.4
SS80-DHAP-CEL Sim substandard 80% APIs 56.2 54.3 56.2 79.4 80.6 81.0
SS80-DHAP-STR Sim substandard 80% APIs 53.7 51.1 54.3 88.5 89.1 85.9
SS50-DHAP-LAC Sim substandard 50% APIs 31.8 30.4 27.6 46.5 47.1 46.1
SS50-DHAP-CEL Sim substandard 50% APIs 29.7 29.3 31.1 52.2 53.4 58.0
SS50-DHAP-STR Sim substandard 50% APIs 31.0 31.1 30.5 48.7 48.0 51.0
EX-LAC Sim falsified 100% excipient ND ND ND ND ND ND
EX-CEL Sim falsified 100% excipient ND ND ND ND ND ND
EX-STR Sim falsified 100% excipient ND ND ND ND ND ND
SM-ACET-LAC
Sim falsified Acetaminophen 
with 0% APIs ND ND ND ND ND ND
SM-ACET-CEL
Sim falsified Acetaminophen 
with 0% APIs ND ND ND ND ND ND
SM-ACET-STR
Sim falsified Acetaminophen 
with 0% APIs ND ND ND ND ND ND
D-Artepp (G552-3) FCGQ 109.8 109.0 111.4 107.0 109.0 110.8





Sample ID Type Of Sample Injection 1 Injection 2 Injection 3
SM-OFLO-LAC Sim 100% APIs 95.3 95.9 95.0
SM-OFLO-CEL Sim 100% APIs 91.1 90.6 84.9
SM-OFLO-STR Sim 100% APIs 99.6 103.2 103.7
SS80-OFLO-LAC-001 Sim substandard 80% APIs 75.5 76.4 75.6
SS80-OFLO-CEL-001 Sim substandard 80% APIs 80.4 81.6 69.4
SS80-OFLO-STR-001 Sim substandard 80% APIs 82.0 86.5 82.3
SS50-OFLO-LAC-001 Sim substandard 50% APIs 54.3 57.3 58.5
SS50-OFLO-CEL-001 Sim substandard 50% APIs 55.1 56.2 57.7
SS50-OFLO-STR-001 Sim substandard 50% APIs 55.8 60.4 58.2
EX-LAC-001 Sim falsified 100% excipient ND ND ND
EX-CEL-001 Sim falsified 100% excipient ND ND ND
EX-STR-001 Sim falsified 100% excipient ND ND ND
SM-ACET-LAC-001








Sim falsified Acetaminophen 
with 0% APIs
ND ND ND
Ofloxin 200 (LA 16-122) FCGQ 95.9 95.8 97.8
Di-Flo 200 (G546) FCGQ 94.5 96.0 91.6
CDP Ofloxacin (G570) FCGQ 84.4 86.9 88.2
Oflocee (G569) FCGQ 105.7 105.2 104.7
















Sample ID Type Of Sample Injection 1 Injection 2 Injection 3 Injection 1 Injection 2 Injection 3
SM-SMTM-LAC Sim 100% APIs 97.1 99.9 97.8 92.3 96.0 97.3
SM-SMTM-CEL Sim 100% APIs 100.1 101.5 106.5 103.7 111.3 113.5
SM-SMTM-STR Sim 100% APIs 100.8 109.8 112.3 91.5 95.4 103.2
SS80-SMTM-LAC Sim substandard 80% APIs 79.2 79.2 77.9 89.7 82.7 81.4
SS80-SMTM-CEL Sim substandard 80% APIs 69.8 69.5 71.8 70.6 74.3 73.0
SS80-SMTM-STR Sim substandard 80% APIs 68.9 71.9 72.6 72.2 72.8 75.2
SS50-SMTM-LAC Sim substandard 50% APIs 41.7 43.1 43.1 65.7 66.7 66.1
SS50-SMTM-CEL Sim substandard 50% APIs 53.1 54.8 52.0 47.9 48.2 45.9
SS50-SMTM-STR Sim substandard 50% APIs 50.7 50.8 51.3 54.9 53.0 51.5
EX-LAC Sim falsified 100% excipient ND ND ND ND ND ND
EX-CEL Sim falsified 100% excipient ND ND ND ND ND ND
EX-STR Sim falsified 100% excipient ND ND ND ND ND ND
SM-ACET-LAC Sim falsified Acetaminophen with 0% APIs ND ND ND ND ND ND
SM-ACET-CEL Sim falsified Acetaminophen with 0% APIs ND ND ND ND ND ND
SM-ACET-STR Sim falsified Acetaminophen with 0% APIs ND ND ND ND ND ND
Bispetrim (G540) FCGQ 98.5 97.9 96.5 99.3 104.6 105.4
Sulfatrim (G571) FCGQ 111.5 116.2 114.9 103.0 105.3 107.7
Strim-side (LA16-70) FCGQ 100.1 96.9 94.5 98.2 99.4 98.9
Vactrim (G556) FCGQ 112.4 106.1 110.2 107.2 107.0 107.2
Griseafulvin (LA13-02) FC Falsified ND ND ND ND ND ND




Calibration Curves for Amoxicillin, Clavulanic Acid, Artemether, Lumefantrine, 





Figure 12: Calibration curves for A, CA, AM, LM, ART, DHA, and P with the 
concentration along the x-axis and the abundances displayed as ion counts along the y-
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